IPO

Global investors inject momentum into Hong Kong’s biotech craze

Big US funds throw weight behind record $21bn in Chinese healthcare listings

International investors including BlackRock and Fidelity are anchoring a boom in Hong Kong biotech listings, with Chinese healthcare companies raising a record $21.1bn from share offerings in the city this year.

Hong Kong is seeking to supplant New York’s Nasdaq as the world’s largest biotech fundraising centre by 2025. The rush of interest from western investors follows reforms two years ago that allowed biotech groups with no revenue to go public in the Asia finance hub for the first time.

Those listings have been backed by so-called cornerstone investors from the US and elsewhere, which in return for a large allocation agree not to sell their shares within six months following an initial public offering.

您已閱讀21%(714字),剩餘79%(2728字)包含更多重要資訊,訂閱以繼續探索完整內容,並享受更多專屬服務。
版權聲明:本文版權歸FT中文網所有,未經允許任何單位或個人不得轉載,複製或以任何其他方式使用本文全部或部分,侵權必究。
設置字型大小×
最小
較小
默認
較大
最大
分享×